A Single-Dose Malaria Drug Shows Promise as Resistance Mutations Race Across Uganda

A single-dose antimalarial drug called cabamiquine has shown promising results in early-stage human trials, offering the potential to replace multi-day treatment regimens that are notoriously difficult to deliver in remote, malaria-ravaged regions. Meanwhile, a separate study published in Nature Medicine reveals that a cluster of drug-resistance mutations in malaria parasites is spreading rapidly across Uganda — underscoring exactly why new drugs like cabamiquine can't...